The ACTC1 Knockout Ca Ski Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Ca Ski cervical carcinoma line, designed to disrupt the ACTC1 gene encoding cardiac ??-actin. This loss-of-function model provides a genetically mixed pool of edited cells, enabling robust functional analyses of ACTC1 in an epithelial context without the constraints of clonal selection. The product facilitates investigation into actin cytoskeletal regulation and associated cellular processes.
The Ca Ski parental line is an epithelial cell model originating from a cervical epidermoid carcinoma metastasis and harbors integrated HPV-16 sequences. These cells are widely utilized in cervical cancer research for probing oncogenic signaling, viral-host interactions, and mechanisms of metastasis. Their epithelial nature makes them suitable for studying genes influencing cytoskeletal architecture and cell motility.
ACTC1 encodes cardiac ??-actin, a core component of sarcomeric thin filaments that interacts with myosin, tropomyosin, and the troponin complex to mediate contraction. In non-muscle cells, ACTC1 participates in actin cytoskeleton organization, affecting cell shape, adhesion, and migration. Its transcription is activated by SRF in cooperation with myocardin and MEF2, and is modulated by TGF-??, GATA4, and mechanical stimuli. Downstream, ACTC1 integrates into actin polymerization dynamics, associating with ??-actinin, nebulin, cofilin, and calponin. Knockout of ACTC1 disrupts these interactions, potentially altering F-actin architecture and impacting the RhoA-ROCK-LIM kinase-cofilin signaling axis, along with focal adhesion constituents such as vinculin, talin, and paxillin.
Within the Ca Ski carcinoma model, ACTC1 knockout allows dissection of cardiac ??-actin??s non-canonical functions in epithelial cancer biology. Although typically muscle-restricted, ACTC1 expression has been observed in certain tumors. Its disruption may remodel actin networks, influencing cell adhesion, migration, and invasion. This model also enables examination of compensation by ??- and ??-actin isoforms and exploration of how actin dynamics interplay with HPV-16-driven oncogenesis.
Applications include western blotting for ACTC1 expression, immunofluorescence with phalloidin to assess F-actin integrity, Boyden chamber and wound healing assays for motility, and co-immunoprecipitation with actin-binding proteins. Transcriptional profiling by RNA-seq can uncover compensatory pathways, while drug sensitivity testing with actin-disrupting agents supports therapeutic target validation. This polyclonal knockout product is ideal for investigating ??-cardiac actin??s role in cytoskeletal dynamics during metastasis and for preclinical cancer drug discovery. For further details, please contact Ascent Research.
